0001950047-24-002199.txt : 20240312
0001950047-24-002199.hdr.sgml : 20240312
20240312162711
ACCESSION NUMBER: 0001950047-24-002199
CONFORMED SUBMISSION TYPE: 144
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20240312
DATE AS OF CHANGE: 20240312
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Avidity Biosciences, Inc.
CENTRAL INDEX KEY: 0001599901
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461336960
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 144
SEC ACT: 1933 Act
SEC FILE NUMBER: 001-39321
FILM NUMBER: 24742477
BUSINESS ADDRESS:
STREET 1: 10578 SCIENCE CENTER DRIVE
STREET 2: SUITE 125
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-401-7900
MAIL ADDRESS:
STREET 1: 10578 SCIENCE CENTER DRIVE
STREET 2: SUITE 125
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Avidity Biosciences LLC
DATE OF NAME CHANGE: 20161227
FORMER COMPANY:
FORMER CONFORMED NAME: Avidity NanoMedicines LLC
DATE OF NAME CHANGE: 20140211
REPORTING-OWNER:
COMPANY DATA:
COMPANY CONFORMED NAME: Boyce Sarah
CENTRAL INDEX KEY: 0001629383
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 144
MAIL ADDRESS:
STREET 1: C/O IONIS PHARMACEUTICALS, INC.
STREET 2: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
144
1
primary_doc.xml
144
0001629383
XXXXXXXX
LIVE
0001599901
AVIDITY BIOSCIENCES INC
001-39321
10578 Science Center Drive, Suite 125
San Diego
CA
92121
8584017900
SARAH BOYCE
Director
Officer
Common
Morgan Stanley Smith Barney LLC Executive Financial Services
1 New York Plaza
8th Floor
New York
NY
10004
84000
1765680.00
79719473
03/12/2024
NASDAQ
Common
03/12/2024
Exercise of Stock Options
Issuer
N
84000
03/12/2024
Cash
N
10b5-1 Sales for SARAH BOYCE
10578 Science Center Drive, Suite 125
San Diego
CA
92121
Common
03/08/2024
84000
1796712.40
10b5-1 Sales for SARAH BOYCE
10578 Science Center Drive, Suite 125
San Diego
CA
92121
Common
03/01/2024
84000
1691309.20
The securities to be sold were and will be received upon the exercise of stock options over the next three months.
03/12/2024
06/09/2023
/s/ Sarah Boyce